Experienced in IgG4-Related Disease

Dr. Flavia V. Castelino

Rheumatology
The General Hospital Corporation
40 2nd Ave, 
Waltham, MA 
Accepting New Patients
Offers Telehealth
Experienced in IgG4-Related Disease
The General Hospital Corporation
40 2nd Ave, 
Waltham, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Flavia Castelino is a Rheumatologist in Waltham, Massachusetts. Dr. Castelino is rated as an Experienced provider by MediFind in the treatment of IgG4-Related Disease. Her top areas of expertise are Scleroderma, Systemic Sclerosis (SSc), Scleroma, and Sjogren Syndrome. Dr. Castelino is currently accepting new patients.

Her clinical research consists of co-authoring 45 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of IgG4-Related Disease.

Specialties
Rheumatology
Licenses
Internal Medicine in MA
Hospital Affiliations
Newton-Wellesley Hospital
Massachusetts General Hospital
North Shore Medical Center -
Cooley Dickinson Hospital Inc,the
Brigham And Women's Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Community Health Options
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health New England
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

THE GENERAL HOSPITAL CORPORATION
40 2nd Ave, Waltham, MA 02451
Other Locations
THE GENERAL HOSPITAL CORPORATION
55 Fruit St, Boston, MA 02114

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Ifetroban in Patients With Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension (SSc-PAH)
A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Ifetroban in Patients With Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension (SSc-PAH)
Enrollment Status: Active_not_recruiting
Publish Date: July 10, 2025
Intervention Type: Drug
Study Drug: Ifetroban
Study Phase: Phase 2
An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Enrollment Status: Terminated
Publish Date: June 11, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
Enrollment Status: Terminated
Publish Date: June 04, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2, Randomized, Placebo-controlled, Double-blind, Open-label Extension Multicenter Study to Evaluate the Efficacy and Safety of Belumosudil (KD025) in Subjects With Diffuse Cutaneous Systemic Sclerosis
A Phase 2, Randomized, Placebo-controlled, Double-blind, Open-label Extension Multicenter Study to Evaluate the Efficacy and Safety of Belumosudil (KD025) in Subjects With Diffuse Cutaneous Systemic Sclerosis
Enrollment Status: Terminated
Publish Date: August 30, 2023
Intervention Type: Drug
Study Drug: Belumosudil (KD025)
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
Enrollment Status: Terminated
Publish Date: March 29, 2021
Intervention Type: Drug, Other
Study Phase: Phase 3
A Phase 2 Study to Evaluate Subcutaneous Abatacept vs. Placebo in Diffuse Cutaneous Systemic Sclerosis- a Double-blind, Placebo-controlled, Randomized Controlled Trial.
A Phase 2 Study to Evaluate Subcutaneous Abatacept vs. Placebo in Diffuse Cutaneous Systemic Sclerosis- a Double-blind, Placebo-controlled, Randomized Controlled Trial.
Enrollment Status: Completed
Publish Date: February 17, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 5 Less Clinical Trials

45 Total Publications

Use of Nintedanib for the Treatment of Systemic Sclerosis-associated Interstitial Lung Disease at Expert Scleroderma Centers in the United States.
Use of Nintedanib for the Treatment of Systemic Sclerosis-associated Interstitial Lung Disease at Expert Scleroderma Centers in the United States.
Journal: Annals of the American Thoracic Society
Published: April 10, 2025
Similar Doctors
Elite in IgG4-Related Disease
Dr. John H. Stone
Rheumatology
Elite in IgG4-Related Disease
Dr. John H. Stone
Rheumatology

Mass General Rheumatology

55 Fruit St, Yawkey Center For Outpatient Care Suite 4B, 
Boston, MA 
 (10.3 miles away)
617-726-7938
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

John Stone is a Rheumatologist in Boston, Massachusetts. Dr. Stone is rated as an Elite provider by MediFind in the treatment of IgG4-Related Disease. His top areas of expertise are IgG4-Related Disease, Giant Cell Arteritis (GCA), Temporal Arteritis, Tissue Biopsy, and Nephrectomy. Dr. Stone is currently accepting new patients.

Elite in IgG4-Related Disease
Dr. Zachary S. Wallace
Rheumatology
Elite in IgG4-Related Disease
Dr. Zachary S. Wallace
Rheumatology

The General Hospital Corporation

55 Fruit St, 
Boston, MA 
 (10.3 miles away)
617-726-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Zachary Wallace is a Rheumatologist in Boston, Massachusetts. Dr. Wallace is rated as an Elite provider by MediFind in the treatment of IgG4-Related Disease. His top areas of expertise are IgG4-Related Disease, Vasculitis, Granulomatosis with Polyangiitis, and End-Stage Renal Disease (ESRD). Dr. Wallace is currently accepting new patients.

Elite in IgG4-Related Disease
Dr. Cory A. Perugino
Rheumatology
Elite in IgG4-Related Disease
Dr. Cory A. Perugino
Rheumatology

Massachusetts General Physicians Organization Inc

55 Fruit St, 
Boston, MA 
 (10.3 miles away)
617-724-0287
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Cory Perugino is a Rheumatologist in Boston, Massachusetts. Dr. Perugino is rated as a Distinguished provider by MediFind in the treatment of IgG4-Related Disease. His top areas of expertise are IgG4-Related Disease, Familial Mixed Cryoglobulinemia, Cryoglobulinemia, and MAGIC Syndrome. Dr. Perugino is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Castelino's expertise for a condition
ConditionClose
View All 13 Advanced Conditions
View All 34 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile